TRAWS PHARMA INC (TRAW) Forecast, Price Target & Analyst Ratings
NASDAQ:TRAW • US68232V8845
1.6 USD
0 (0%)
Last: Mar 6, 2026, 08:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TRAWS PHARMA INC (TRAW).
Forecast Snapshot
Consensus Price Target
$7.40
+ 362.19% Upside
Next Earnings Forecast
Release DateMar 30, 2026
PeriodQ4 / 2025
EPS Estimate-$1.25
Revenue Estimate
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$7.40
Upside
+ 362.19%
From current price of $1.60 to mean target of $7.40, Based on 7 analyst forecasts
Low
$6.57
Median
$7.40
High
$8.40
Price Target Revisions
1 Month
-9.38%
3 Months
-95.17%
Price Target Summary
7 analysts have analysed TRAW and the average price target is 7.4 USD. This implies a price increase of 362.19% is expected in the next year compared to the current price of 1.6.
The average price target has been revised downward by 95.17% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
TRAW was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about TRAW.
In the previous month the buy percentage consensus was at a similar level.
TRAW was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-03 | HC Wainwright & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 30, 2026
PeriodQ4 / 2025
EPS Estimate-$1.25
Revenue Estimate
Revenue Q2Q-100.00%
EPS Q2Q-101.31%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
-100.00%
EPS (1 Month)
35.92%
EPS (3 Months)
87.20%
Next Earnings Summary
TRAW is expected to report earnings on 3/30/2026. The consensus EPS estimate for the next earnings is -1.25 USD and the consensus revenue estimate is 0 USD.
The next earnings revenue estimate has been revised downward by 100% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 226K | 226K | 226K | 2.856M 1,163.72% | -100.00% | 26.724M | 58.242M 117.94% | 156.77M 169.17% | 246.43M 57.19% | 308.04M 25.00% | 338.03M 9.74% | 369.95M 9.44% | |
| EBITDA YoY % growth | -19.613M -19.00% | -20.282M -3.41% | -24.898M -22.76% | -29.172M -17.17% | -33.864M -16.08% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -19.627M -18.98% | -20.298M -3.42% | -24.91M -22.72% | -21.777M 12.58% | -46.308M -112.65% | -46.614M -0.66% | -44.217M 5.14% | -6.834M 84.54% | 56.916M 932.84% | 100.62M 76.79% | 138.06M 37.21% | 175.64M 27.22% | |
| Operating Margin | -8,684.51% | -8,981.42% | -11,022.12% | -762.50% | N/A | -174.43% | -75.92% | -4.36% | 23.10% | 32.66% | 40.84% | 47.48% | |
| EPS YoY % growth | -22.75 3.19% | -22.50 1.10% | N/A -599.72% | -0.04 99.97% | -2.35 -5,650.00% | -1.32 43.91% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.25 -101.31% | -0.79 90.32% | -0.55 93.83% | -0.51 94.54% | -0.57 54.25% |
| Revenue Q2Q % growth | -100.00% | -100.00% | -100.00% | ||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -17.238M -226.48% | -8.976M -72.52% | -10.2M -716.65% | -10.302M -154.06% | -10.506M 39.05% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.82%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
384.76%
Revenue Next 5 Year
267.27%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
TRAWS PHARMA INC / TRAW Forecast FAQ
What is the price target for TRAW stock?
7 analysts have analysed TRAW and the average price target is 7.4 USD. This implies a price increase of 362.19% is expected in the next year compared to the current price of 1.6.
What is the next earnings date for TRAW stock?
TRAWS PHARMA INC (TRAW) will report earnings on 2026-03-30, after the market close.
What are the consensus estimates for TRAWS PHARMA INC (TRAW) next earnings?
The consensus EPS estimate for the next earnings of TRAWS PHARMA INC (TRAW) is -1.25 USD and the consensus revenue estimate is 0 USD.
What is the number of analysts for TRAW stock?
The number of analysts covering TRAWS PHARMA INC (TRAW) is 7.